Thr177
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr177  -  CAMK1A (human)

Site Information
DPGsVLstACGTPGY   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448527

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 3 , 5 , 6 , 7 , 8 ) , phospho-antibody ( 1 , 2 , 4 ) , western blotting ( 2 , 4 )
Disease tissue studied:
pancreatic cancer ( 1 ) , prostate cancer ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
QIK (human) ( 2 )
Kinases, in vitro:
CAMKK1 (human) ( 9 )
Putative upstream phosphatases:
PPP2CA (human) ( 2 )
Phosphatases, in vitro:
PPP2CA (human) ( 2 )
Treatments:
carbachol ( 4 ) , KN-93 ( 4 ) , okadaic_acid ( 2 ) , STO-609 ( 4 )

Downstream Regulation
Effects of modification on CAMK1A:
enzymatic activity, induced ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
pancreatic ductal adenocarcinoma ( 1 )

References 

1

Tan X, et al. (2016) Phosphoproteome Analysis of Invasion and Metastasis-Related Factors in Pancreatic Cancer Cells. PLoS One 11, e0152280
27014871   Curated Info

2

Lee CW, et al. (2014) Interaction between Salt-inducible Kinase 2 and Protein Phosphatase 2A Regulates the Activity of Calcium/Calmodulin-dependent Protein Kinase I and Protein Phosphatase Methylesterase-1. J Biol Chem 289, 21108-21119
24841198   Curated Info

3

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

4

Schmitt JM, Smith S, Hart B, Fletcher L (2012) CaM kinase control of AKT and LNCaP cell survival. J Cell Biochem 113, 1514-26
22173970   Curated Info

5

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

6

Zhou J (2009) CST Curation Set: 7598; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

7

Zhou J (2009) CST Curation Set: 7592; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

8

Zhou J (2009) CST Curation Set: 7591; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

9

Haribabu B, et al. (1995) Human calcium-calmodulin dependent protein kinase I: cDNA cloning, domain structure and activation by phosphorylation at threonine-177 by calcium-calmodulin dependent protein kinase I kinase. EMBO J 14, 3679-86
7641687   Curated Info